Vogt‐Koyanagi‐Harada disease‐like posterior uveitis in the course of nivolumab (anti‐PD‐1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma

Abstract

A patient with metastatic cutaneous malignant melanoma developed Vogt‐Koyanagi‐Harada disease‐like posterior uveitis after two nivolumab (anti‐PD‐1 antibody) injections. Vogt‐Koyanagi‐Harada disease, with the background of autoimmunity against choroidal melanocytes, suggests nivolumab be working by disintegrating inhibition circuit of T cells against a common epitope shared between melanoma cells and normal melanocytes.